SAFC launches new CHO lines for protein drug developers

- Last updated on GMT

Related tags: Dna, Safc

SAFC launches two new CHO lines for protein drug developers
SAFC launches two new CHO lines for protein drug developers
A new knock-out cell line developed by SAFC promises to make crystallography studies more effective and –potentially – safer therapeutic proteins.

The new line is the latest addition to the portfolio of modified Chinese hamster ovary (CHO) cells developed using SAFC’s zinc-finger nuclease (ZFN) technology and lacks the gene encoding MGAT-1, which is a key enzyme involved in protein glycosylation.

Cell lines that lack the MGAT-1 enzyme means make proteins that have a uniform N-glycan profile, because the synthesis pathway is halted before later steps that introduce the variations that make crystallography studies of glycosylated proteins a challenge​ according to SAFC.

A knockout of the MGAT1 gene function results in early termination of the N-glycan pathway and enables the expression of recombinant proteins with homogeneous high Man5 glycan profiles. This is useful for protein crystallography studies as well as for the expression of biotherapeutics that target mannose receptors.​ “

SAFC also rolled out another new CHO variation.

The second knockout cell line – which was made using the ZFN technology - make proteins that do not contain galactose-alpha-1,3-galactose or N​-Glycolylneuraminic acid, which are both known to cause allergic reactions.

Zinc-finger business

The news follows just a few weeks after licensed its ZFN technology to contract services firm Horizon Discovery​. At the time Horizon CEO Darrin Disley told BioPharma-Reporter.com that: "Both [Horizon's own] rAAV and nuclease-based technologies have their strengths and limitations, and so are bestapplied in diferent situations​."

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

How Viral Safety Testing Will Evolve

How Viral Safety Testing Will Evolve

Viral Safety for mAb: Prevent, Detect, Remove | 20-May-2020 | Event Programme

The pressure to shorten delivery times and reduce costs for biologics are driving an evolution in the biomanufacturing space. Many of the methods used...

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Related suppliers

Follow us

Products

View more

Webinars